Microsurgical Resection of Subependymal Giant Cell Astrocytoma: Single-Center Retrospective Analysis and Meta-Analysis
BACKGROUND AND OBJECTIVES: Subependymal giant cell astrocytomas (SEGA) are low-grade intraventricular tumors generally associated with tuberous sclerosis complex. Although mechanistic target of rapamycin inhibitors are recommended as first-line therapy for progressive SEGA without hydrocephalus, surgery is still relevant because 40% of patients are drug resistant. This study aimed to evaluate surgical outcomes in terms of tumor control, complication rates, and ventriculoperitoneal shunt (VPS) requirement, through a single-center retrospective series and a meta-analysis. METHODS: We retrospectively analyzed 31 pediatric SEGA resections performed over 2 decades at a tertiary care center. Clinical, radiological, and surgical variables were examined to identify predictors of outcome. In addition, a systematic literature review and meta-analysis were conducted to contextualize our findings. RESULTS: Gross total resection was achieved in 64.5% of cases, with a 19.3% rate of transient postoperative complications and a 6.4% incidence of VPS placement. No permanent morbidity or mortality occurred. Favorable outcome was associated with a smaller tumor volume and absence of preoperative hydrocephalus. The meta-analysis confirmed that preoperative hydrocephalus was the main predictor of postoperative complications (odds ratio 2.30) and shunt dependence (odds ratio 3.45). Five-year progression-free survival was 90.9% in the gross total resection subgroup and 100% in patients with unilateral tumors. Bilateral tumor location was an independent predictor of recurrence (hazard ratio = 17.79, P = .02). CONCLUSION: Microsurgical resection of SEGA is a safe and effective therapeutic option, particularly in patients without hydrocephalus. Early surgical intervention may reduce the need for VPS and long-term complications, offering a valid alternative or complement to mechanistic target of rapamycin inhibitor therapy, with durable tumor control especially in unilateral cases.
Authors
- Nicole Chémaly (ORCID: https://orcid.org/0000-0002-2333-9408)
- Rima Nabbout (ORCID: https://orcid.org/0000-0001-5877-4074)
- Lelio Guida (ORCID: https://orcid.org/0000-0001-6981-6698)
- Thomas Blauwblomme (ORCID: https://orcid.org/0000-0003-4076-9642)
- Luca Sartori (ORCID: https://orcid.org/0000-0002-0041-0734)
- Kévin Beccaria (ORCID: https://orcid.org/0000-0002-3405-1944)
- Nathalie Boddaert (ORCID: https://orcid.org/0000-0003-0991-7774)
- Pascale Varlet
- Marie Bourgeois
- Stéphanie Puget
- Volodia Dangoulof-Ros
Institutions
- Hôpital Necker-Enfants Malades (FR)
- University of Padua (IT)
- Inserm (FR)
- Université Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre Hospitalier Sainte-Anne (FR)
- Epilepsy Foundation (AU)
- Action Network (US)
- Institut des Maladies Génétiques Imagine (FR)
Publication Details
- Journal
- Neurosurgery
- Published
- 2026-04-13
- DOI
- https://doi.org/10.1227/neu.0000000000004044
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00